Login to Your Account



Regulatory NEWS

FDA briefing documents released Friday morning in advance of Tuesday's Arthritis Advisory Committee Meeting (adcom) suggested the agency will go gentle on the biologics license application for CT-P13, Celltrion Inc.'s biosimilar to Remicade (infliximab, Janssen Biotech Inc.) that is approved elsewhere as Remsima (infliximab).

Delays in putting out much-needed guidance earned the FDA a C+ Thursday in its implementation of the biosimilar path, but the Centers for Medicare & Medicaid Services (CMS) got a D- for not even trying.

HONG KONG – The Korean Ministry of Food and Drug Safety (MFDS) is shortening the biologics review process for rare and incurable diseases to speed up the approvals and overseas distribution of Korea-developed biopharmaceuticals.

More Regulatory Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: